This project aims to help to develop antibodies against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 involved in recognizing a host cell-surface receptor, namely, zinc peptidase angiotensinconverting enzyme 2. Another objective is to develop unsaturated free fatty acid-based emulsion loaded in-situ gels to inactivate the virus at the point of entry.
Accessibility Controls